Montefiore Einstein’s lung cancer team earns international recognition

Brown University names the Giuliani RNA Center in recognition of gift

Brown University will name its emerging research center focused on RNA science the Giuliani RNA Center, in recognition of a gift from health care investor and Brown trustee Giammaria Giuliani and his wife, Sabrina.

October 03, 2025

Vol.51 No.36

In Brief

Curebound Cancer Challenge raises $4M to fund research in San Diego

Over 3,000 riders, runners, walkers, and spinners joined forces at UC San Diego last month for the 2025 Curebound Cancer Challenge (formerly Padres Pedal the Cause), generating $4 million to advance cancer research in the San Diego region.

October 03, 2025

Vol.51 No.36

In Brief

The Parker Institute for Cancer Immunotherapy awards over $1M to five early-stage career cancer researchers

The Parker Institute for Cancer Immunotherapy, a collaborative consortium of immuno-oncology experts that bridges scientific discovery and commercialization of cancer therapies, announced its 2025 class of Early Career Researcher awardees.

October 03, 2025

Vol.51 No.36

In Brief

Montefiore Einstein Comprehensive Cancer Center’s lung cancer team earns international recognition

Montefiore Einstein Comprehensive Cancer Center announced that its lung cancer team has been recognized by the International Association for the Study of Lung Cancer for delivering outstanding care. The announcement was made during the IASLC annual meeting in Barcelona.

October 03, 2025

Vol.51 No.36

Clinical Roundup

American Lung Association launches campaign to address barriers to lung cancer screening and care

The American Lung Association launched a campaign to raise awareness about lung cancer screening and biomarker testing, shaped by the voices of people diagnosed with lung cancer and their caregivers across the country.

October 03, 2025

Vol.51 No.36

Drugs & Targets

FDA approves Zepzelca + Tecentriq combination as first-line maintenance therapy for ES-SCLC

FDA has granted a approval for Zepzelca (lurbinectedin) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as a maintenance treatment for adults with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.

October 03, 2025

Vol.51 No.36

Montefiore Einstein’s lung cancer team earns international recognition

YOU MAY BE INTERESTED IN

Brown University names the Giuliani RNA Center in recognition of gift

Curebound Cancer Challenge raises $4M to fund research in San Diego

The Parker Institute for Cancer Immunotherapy awards over $1M to five early-stage career cancer researchers

Montefiore Einstein Comprehensive Cancer Center’s lung cancer team earns international recognition

American Lung Association launches campaign to address barriers to lung cancer screening and care

FDA approves Zepzelca + Tecentriq combination as first-line maintenance therapy for ES-SCLC

Renew today!

Subscriber content

Never miss an issue!

Login